Even in multiple myeloma, where IL-6 is recognized as a critical growth factor driving tumor cell proliferation and survival, the clinical efficacy of anti-IL-6 mAbs has been disappointing—despite anecdotal reports of transient benefits in select patient subgroups [208]. This evidence concerns the gene IL6 and plasma cell myeloma.